+357 96 030922
info@marketpublishers.com

Global Leukotriene Receptor Antagonists for Asthma and COPD Market Growth 2026-2032

https://marketpublishers.com/r/G0629D32E24FEN.html
Date: October 2026
Pages: 122
Price: US$ 3,660.00 (Single User License)
ID: G0629D32E24FEN

Abstracts

The global Leukotriene Receptor Antagonists for Asthma and COPD market size is predicted to grow from US$ 1303 million in 2025 to US$ 1812 million in 2032; it is expected to grow at a CAGR of 4.9% from 2026 to 2032.

Leukotriene receptor antagonists (LTRAs) for asthma and COPD are oral medications that selectively inhibit the CysLT1 receptor, blocking leukotriene-mediated inflammatory signaling. This action helps reduce airway inflammation, relieve bronchoconstriction, and alleviate symptoms in asthma and certain COPD patients. Representative drugs include Montelukast, primarily used for long-term management of mild-to-moderate asthma and as adjunct therapy for COPD patients, particularly for those who cannot tolerate inhalers or prefer oral administration.

Upstream raw materials consist of pharmaceutical-grade fine chemicals, such as quinoline derivatives, pyridine derivatives, and amide intermediates. Key suppliers are concentrated in India, China, and Europe/USA, with leading companies including Cipla, Hetero Labs, Sun Pharmaceutical (India), and Huahai Pharmaceutical (China), all of which have strong capabilities in API synthesis, quality control, and large-scale supply. Downstream customers mainly include global pharmaceutical companies, generic drug manufacturers, and healthcare institutions, distributing the finished products through hospitals, retail pharmacies, and e-commerce channels to end patients. With the rising prevalence of chronic respiratory diseases and increasing demand for long-term disease management, the market for LTRAs remains stable, driving continuous optimization of the API supply chain and formulation processes.

In 2024, the global average price of leukotriene receptor antagonists for asthma and COPD is approximately USD 0.24 per tablet, with total sales reaching about 5.263

+357 96 030922
info@marketpublishers.com

billion tablets.

United States market for Leukotriene Receptor Antagonists for Asthma and COPD is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

China market for Leukotriene Receptor Antagonists for Asthma and COPD is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

Europe market for Leukotriene Receptor Antagonists for Asthma and COPD is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

Global key Leukotriene Receptor Antagonists for Asthma and COPD players cover Hetero Drugs, Aurobindo Pharma, Organon Pharma, Kyorin Holdings, Unichem Laboratories, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.

Report Scope

LP Information, Inc. (LPI) ' newest research report, the “Leukotriene Receptor Antagonists for Asthma and COPD Industry Forecast” looks at past sales and reviews total world Leukotriene Receptor Antagonists for Asthma and COPD sales in 2025, providing a comprehensive analysis by region and market sector of projected Leukotriene Receptor Antagonists for Asthma and COPD sales for 2026 through 2032. With Leukotriene Receptor Antagonists for Asthma and COPD sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Leukotriene Receptor Antagonists for Asthma and COPD industry.

This Insight Report provides a comprehensive analysis of the global Leukotriene Receptor Antagonists for Asthma and COPD landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Leukotriene Receptor Antagonists for Asthma and COPD portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Leukotriene Receptor Antagonists for Asthma and COPD market.

+357 96 030922
info@marketpublishers.com

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Leukotriene Receptor Antagonists for Asthma and COPD and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Leukotriene Receptor Antagonists for Asthma and COPD.

This report presents a comprehensive overview, market shares, and growth opportunities of Leukotriene Receptor Antagonists for Asthma and COPD market by product type, application, key manufacturers and key regions and countries.

Market Segmentation

Segmentation by Type:

Montelukast

Zileuton

Others

Segmentation by Application:

Hospital

Clinic

Others

This report also splits the market by region:

Americas

United States

+357 96 030922
info@marketpublishers.com

- Canada
- Mexico
- Brazil

APAC

- China
- Japan
- Korea
- Southeast Asia
- India
- Australia

Europe

- Germany
- France
- UK
- Italy
- Russia

Middle East & Africa

- Egypt
- South Africa
- Israel

+357 96 030922
info@marketpublishers.com

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Hetero Drugs

Aurobindo Pharma

Organon Pharma

Kyorin Holdings

Unichem Laboratories

Dr Reddy's Laboratories

Rising Pharma

Chiesi Farmaceutici

Strides Pharma

Shanghai Anbison

CSPC Ouyi Pharmaceutical

Key Questions Addressed in this Report

What is the 10-year outlook for the global Leukotriene Receptor Antagonists for Asthma and COPD market?

+357 96 030922
info@marketpublishers.com

What factors are driving Leukotriene Receptor Antagonists for Asthma and COPD market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Leukotriene Receptor Antagonists for Asthma and COPD market opportunities vary by end market size?

How does Leukotriene Receptor Antagonists for Asthma and COPD break out by Type, by Application?

+357 96 030922
info@marketpublishers.com

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Leukotriene Receptor Antagonists for Asthma and COPD Annual Sales 2021-2032
  2.1.2 World Current & Future Analysis for Leukotriene Receptor Antagonists for Asthma and COPD by Geographic Region, 2021, 2025 & 2032
  2.1.3 World Current & Future Analysis for Leukotriene Receptor Antagonists for Asthma and COPD by Country/Region, 2021, 2025 & 2032
2.2 Leukotriene Receptor Antagonists for Asthma and COPD Segment by Type
  2.2.1 Montelukast
  2.2.2 Zileuton
  2.2.3 Others
  2.2.4 Leukotriene Receptor Antagonists for Asthma and COPD Sales by Type
    2.2.4.1 Global Leukotriene Receptor Antagonists for Asthma and COPD Sales Market Share by Type (2021-2026)
    2.2.4.2 Global Leukotriene Receptor Antagonists for Asthma and COPD Revenue and Market Share by Type (2021-2026)
    2.2.4.3 Global Leukotriene Receptor Antagonists for Asthma and COPD Sale Price by Type (2021-2026)
2.3 Leukotriene Receptor Antagonists for Asthma and COPD Segment by Application
  2.3.1 Hospital
  2.3.2 Clinic
  2.3.3 Others
  2.3.4 Leukotriene Receptor Antagonists for Asthma and COPD Sales by Application
    2.3.4.1 Global Leukotriene Receptor Antagonists for Asthma and COPD Sale Market

+357 96 030922
info@marketpublishers.com

Share by Application (2021-2026)
2.3.4.2 Global Leukotriene Receptor Antagonists for Asthma and COPD Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global Leukotriene Receptor Antagonists for Asthma and COPD Sale Price by Application (2021-2026)

3 GLOBAL BY COMPANY

3.1 Global Leukotriene Receptor Antagonists for Asthma and COPD Breakdown Data by Company
3.1.1 Global Leukotriene Receptor Antagonists for Asthma and COPD Annual Sales by Company (2021-2026)
3.1.2 Global Leukotriene Receptor Antagonists for Asthma and COPD Sales Market Share by Company (2021-2026)
3.2 Global Leukotriene Receptor Antagonists for Asthma and COPD Annual Revenue by Company (2021-2026)
3.2.1 Global Leukotriene Receptor Antagonists for Asthma and COPD Revenue by Company (2021-2026)
3.2.2 Global Leukotriene Receptor Antagonists for Asthma and COPD Revenue Market Share by Company (2021-2026)
3.3 Global Leukotriene Receptor Antagonists for Asthma and COPD Sale Price by Company
3.4 Key Manufacturers Leukotriene Receptor Antagonists for Asthma and COPD Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Leukotriene Receptor Antagonists for Asthma and COPD Product Location Distribution
3.4.2 Players Leukotriene Receptor Antagonists for Asthma and COPD Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR LEUKOTRIENE RECEPTOR ANTAGONISTS FOR ASTHMA AND COPD BY GEOGRAPHIC REGION

4.1 World Historic Leukotriene Receptor Antagonists for Asthma and COPD Market Size by Geographic Region (2021-2026)

+357 96 030922
info@marketpublishers.com

4.1.1 Global Leukotriene Receptor Antagonists for Asthma and COPD Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Leukotriene Receptor Antagonists for Asthma and COPD Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Leukotriene Receptor Antagonists for Asthma and COPD Market Size by Country/Region (2021-2026)
4.2.1 Global Leukotriene Receptor Antagonists for Asthma and COPD Annual Sales by Country/Region (2021-2026)
4.2.2 Global Leukotriene Receptor Antagonists for Asthma and COPD Annual Revenue by Country/Region (2021-2026)
4.3 Americas Leukotriene Receptor Antagonists for Asthma and COPD Sales Growth
4.4 APAC Leukotriene Receptor Antagonists for Asthma and COPD Sales Growth
4.5 Europe Leukotriene Receptor Antagonists for Asthma and COPD Sales Growth
4.6 Middle East & Africa Leukotriene Receptor Antagonists for Asthma and COPD Sales Growth

5 AMERICAS

5.1 Americas Leukotriene Receptor Antagonists for Asthma and COPD Sales by Country
5.1.1 Americas Leukotriene Receptor Antagonists for Asthma and COPD Sales by Country (2021-2026)
5.1.2 Americas Leukotriene Receptor Antagonists for Asthma and COPD Revenue by Country (2021-2026)
5.2 Americas Leukotriene Receptor Antagonists for Asthma and COPD Sales by Type (2021-2026)
5.3 Americas Leukotriene Receptor Antagonists for Asthma and COPD Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Leukotriene Receptor Antagonists for Asthma and COPD Sales by Region
6.1.1 APAC Leukotriene Receptor Antagonists for Asthma and COPD Sales by Region (2021-2026)
6.1.2 APAC Leukotriene Receptor Antagonists for Asthma and COPD Revenue by

+357 96 030922
info@marketpublishers.com

Region (2021-2026)
6.2 APAC Leukotriene Receptor Antagonists for Asthma and COPD Sales by Type (2021-2026)
6.3 APAC Leukotriene Receptor Antagonists for Asthma and COPD Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan

7 EUROPE

7.1 Europe Leukotriene Receptor Antagonists for Asthma and COPD by Country
  7.1.1 Europe Leukotriene Receptor Antagonists for Asthma and COPD Sales by Country (2021-2026)
  7.1.2 Europe Leukotriene Receptor Antagonists for Asthma and COPD Revenue by Country (2021-2026)
7.2 Europe Leukotriene Receptor Antagonists for Asthma and COPD Sales by Type (2021-2026)
7.3 Europe Leukotriene Receptor Antagonists for Asthma and COPD Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Leukotriene Receptor Antagonists for Asthma and COPD by Country
  8.1.1 Middle East & Africa Leukotriene Receptor Antagonists for Asthma and COPD Sales by Country (2021-2026)
  8.1.2 Middle East & Africa Leukotriene Receptor Antagonists for Asthma and COPD Revenue by Country (2021-2026)
8.2 Middle East & Africa Leukotriene Receptor Antagonists for Asthma and COPD

+357 96 030922
info@marketpublishers.com

Sales by Type (2021-2026)
8.3 Middle East & Africa Leukotriene Receptor Antagonists for Asthma and COPD Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Leukotriene Receptor Antagonists for Asthma and COPD
10.3 Manufacturing Process Analysis of Leukotriene Receptor Antagonists for Asthma and COPD
10.4 Industry Chain Structure of Leukotriene Receptor Antagonists for Asthma and COPD

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel
  11.1.1 Direct Channels
  11.1.2 Indirect Channels
11.2 Leukotriene Receptor Antagonists for Asthma and COPD Distributors
11.3 Leukotriene Receptor Antagonists for Asthma and COPD Customer

12 WORLD FORECAST REVIEW FOR LEUKOTRIENE RECEPTOR ANTAGONISTS FOR ASTHMA AND COPD BY GEOGRAPHIC REGION

12.1 Global Leukotriene Receptor Antagonists for Asthma and COPD Market Size Forecast by Region
  12.1.1 Global Leukotriene Receptor Antagonists for Asthma and COPD Forecast by

+357 96 030922
info@marketpublishers.com

Region (2027-2032)
12.1.2 Global Leukotriene Receptor Antagonists for Asthma and COPD Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Leukotriene Receptor Antagonists for Asthma and COPD Forecast by Type (2027-2032)
12.7 Global Leukotriene Receptor Antagonists for Asthma and COPD Forecast by Application (2027-2032)

13 KEY PLAYERS ANALYSIS

13.1 Hetero Drugs
13.1.1 Hetero Drugs Company Information
13.1.2 Hetero Drugs Leukotriene Receptor Antagonists for Asthma and COPD Product Portfolios and Specifications
13.1.3 Hetero Drugs Leukotriene Receptor Antagonists for Asthma and COPD Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Hetero Drugs Main Business Overview
13.1.5 Hetero Drugs Latest Developments
13.2 Aurobindo Pharma
13.2.1 Aurobindo Pharma Company Information
13.2.2 Aurobindo Pharma Leukotriene Receptor Antagonists for Asthma and COPD Product Portfolios and Specifications
13.2.3 Aurobindo Pharma Leukotriene Receptor Antagonists for Asthma and COPD Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Aurobindo Pharma Main Business Overview
13.2.5 Aurobindo Pharma Latest Developments
13.3 Organon Pharma
13.3.1 Organon Pharma Company Information
13.3.2 Organon Pharma Leukotriene Receptor Antagonists for Asthma and COPD Product Portfolios and Specifications
13.3.3 Organon Pharma Leukotriene Receptor Antagonists for Asthma and COPD Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Organon Pharma Main Business Overview
13.3.5 Organon Pharma Latest Developments
13.4 Kyorin Holdings

+357 96 030922
info@marketpublishers.com

13.4.1 Kyorin Holdings Company Information
13.4.2 Kyorin Holdings Leukotriene Receptor Antagonists for Asthma and COPD Product Portfolios and Specifications
13.4.3 Kyorin Holdings Leukotriene Receptor Antagonists for Asthma and COPD Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Kyorin Holdings Main Business Overview
13.4.5 Kyorin Holdings Latest Developments
13.5 Unichem Laboratories
13.5.1 Unichem Laboratories Company Information
13.5.2 Unichem Laboratories Leukotriene Receptor Antagonists for Asthma and COPD Product Portfolios and Specifications
13.5.3 Unichem Laboratories Leukotriene Receptor Antagonists for Asthma and COPD Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Unichem Laboratories Main Business Overview
13.5.5 Unichem Laboratories Latest Developments
13.6 Dr Reddy's Laboratories
13.6.1 Dr Reddy's Laboratories Company Information
13.6.2 Dr Reddy's Laboratories Leukotriene Receptor Antagonists for Asthma and COPD Product Portfolios and Specifications
13.6.3 Dr Reddy's Laboratories Leukotriene Receptor Antagonists for Asthma and COPD Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Dr Reddy's Laboratories Main Business Overview
13.6.5 Dr Reddy's Laboratories Latest Developments
13.7 Rising Pharma
13.7.1 Rising Pharma Company Information
13.7.2 Rising Pharma Leukotriene Receptor Antagonists for Asthma and COPD Product Portfolios and Specifications
13.7.3 Rising Pharma Leukotriene Receptor Antagonists for Asthma and COPD Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Rising Pharma Main Business Overview
13.7.5 Rising Pharma Latest Developments
13.8 Chiesi Farmaceutici
13.8.1 Chiesi Farmaceutici Company Information
13.8.2 Chiesi Farmaceutici Leukotriene Receptor Antagonists for Asthma and COPD Product Portfolios and Specifications
13.8.3 Chiesi Farmaceutici Leukotriene Receptor Antagonists for Asthma and COPD Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Chiesi Farmaceutici Main Business Overview
13.8.5 Chiesi Farmaceutici Latest Developments

+357 96 030922
info@marketpublishers.com

13.9 Strides Pharma
13.9.1 Strides Pharma Company Information
13.9.2 Strides Pharma Leukotriene Receptor Antagonists for Asthma and COPD Product Portfolios and Specifications
13.9.3 Strides Pharma Leukotriene Receptor Antagonists for Asthma and COPD Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Strides Pharma Main Business Overview
13.9.5 Strides Pharma Latest Developments
13.10 Shanghai Anbison
13.10.1 Shanghai Anbison Company Information
13.10.2 Shanghai Anbison Leukotriene Receptor Antagonists for Asthma and COPD Product Portfolios and Specifications
13.10.3 Shanghai Anbison Leukotriene Receptor Antagonists for Asthma and COPD Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Shanghai Anbison Main Business Overview
13.10.5 Shanghai Anbison Latest Developments
13.11 CSPC Ouyi Pharmaceutical
13.11.1 CSPC Ouyi Pharmaceutical Company Information
13.11.2 CSPC Ouyi Pharmaceutical Leukotriene Receptor Antagonists for Asthma and COPD Product Portfolios and Specifications
13.11.3 CSPC Ouyi Pharmaceutical Leukotriene Receptor Antagonists for Asthma and COPD Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 CSPC Ouyi Pharmaceutical Main Business Overview
13.11.5 CSPC Ouyi Pharmaceutical Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

+357 96 030922
info@marketpublishers.com

List Of Tables

LIST OF TABLES

Table 1. Leukotriene Receptor Antagonists for Asthma and COPD Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Leukotriene Receptor Antagonists for Asthma and COPD Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Montelukast
Table 4. Major Players of Zileuton
Table 5. Major Players of Others
Table 6. Global Leukotriene Receptor Antagonists for Asthma and COPD Sales by Type (2021-2026) & (K Units)
Table 7. Global Leukotriene Receptor Antagonists for Asthma and COPD Sales Market Share by Type (2021-2026)
Table 8. Global Leukotriene Receptor Antagonists for Asthma and COPD Revenue by Type (2021-2026) & ($ million)
Table 9. Global Leukotriene Receptor Antagonists for Asthma and COPD Revenue Market Share by Type (2021-2026)
Table 10. Global Leukotriene Receptor Antagonists for Asthma and COPD Sale Price by Type (2021-2026) & (US$/Unit)
Table 11. Global Leukotriene Receptor Antagonists for Asthma and COPD Sale by Application (2021-2026) & (K Units)
Table 12. Global Leukotriene Receptor Antagonists for Asthma and COPD Sale Market Share by Application (2021-2026)
Table 13. Global Leukotriene Receptor Antagonists for Asthma and COPD Revenue by Application (2021-2026) & ($ million)
Table 14. Global Leukotriene Receptor Antagonists for Asthma and COPD Revenue Market Share by Application (2021-2026)
Table 15. Global Leukotriene Receptor Antagonists for Asthma and COPD Sale Price by Application (2021-2026) & (US$/Unit)
Table 16. Global Leukotriene Receptor Antagonists for Asthma and COPD Sales by Company (2021-2026) & (K Units)
Table 17. Global Leukotriene Receptor Antagonists for Asthma and COPD Sales Market Share by Company (2021-2026)
Table 18. Global Leukotriene Receptor Antagonists for Asthma and COPD Revenue by Company (2021-2026) & ($ millions)
Table 19. Global Leukotriene Receptor Antagonists for Asthma and COPD Revenue Market Share by Company (2021-2026)

+357 96 030922
info@marketpublishers.com

Table 20. Global Leukotriene Receptor Antagonists for Asthma and COPD Sale Price by Company (2021-2026) & (US$/Unit)
Table 21. Key Manufacturers Leukotriene Receptor Antagonists for Asthma and COPD Producing Area Distribution and Sales Area
Table 22. Players Leukotriene Receptor Antagonists for Asthma and COPD Products Offered
Table 23. Leukotriene Receptor Antagonists for Asthma and COPD Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global Leukotriene Receptor Antagonists for Asthma and COPD Sales by Geographic Region (2021-2026) & (K Units)
Table 27. Global Leukotriene Receptor Antagonists for Asthma and COPD Sales Market Share Geographic Region (2021-2026)
Table 28. Global Leukotriene Receptor Antagonists for Asthma and COPD Revenue by Geographic Region (2021-2026) & ($ millions)
Table 29. Global Leukotriene Receptor Antagonists for Asthma and COPD Revenue Market Share by Geographic Region (2021-2026)
Table 30. Global Leukotriene Receptor Antagonists for Asthma and COPD Sales by Country/Region (2021-2026) & (K Units)
Table 31. Global Leukotriene Receptor Antagonists for Asthma and COPD Sales Market Share by Country/Region (2021-2026)
Table 32. Global Leukotriene Receptor Antagonists for Asthma and COPD Revenue by Country/Region (2021-2026) & ($ millions)
Table 33. Global Leukotriene Receptor Antagonists for Asthma and COPD Revenue Market Share by Country/Region (2021-2026)
Table 34. Americas Leukotriene Receptor Antagonists for Asthma and COPD Sales by Country (2021-2026) & (K Units)
Table 35. Americas Leukotriene Receptor Antagonists for Asthma and COPD Sales Market Share by Country (2021-2026)
Table 36. Americas Leukotriene Receptor Antagonists for Asthma and COPD Revenue by Country (2021-2026) & ($ millions)
Table 37. Americas Leukotriene Receptor Antagonists for Asthma and COPD Sales by Type (2021-2026) & (K Units)
Table 38. Americas Leukotriene Receptor Antagonists for Asthma and COPD Sales by Application (2021-2026) & (K Units)
Table 39. APAC Leukotriene Receptor Antagonists for Asthma and COPD Sales by Region (2021-2026) & (K Units)
Table 40. APAC Leukotriene Receptor Antagonists for Asthma and COPD Sales Market

+357 96 030922
info@marketpublishers.com

Share by Region (2021-2026)
Table 41. APAC Leukotriene Receptor Antagonists for Asthma and COPD Revenue by Region (2021-2026) & ($ millions)
Table 42. APAC Leukotriene Receptor Antagonists for Asthma and COPD Sales by Type (2021-2026) & (K Units)
Table 43. APAC Leukotriene Receptor Antagonists for Asthma and COPD Sales by Application (2021-2026) & (K Units)
Table 44. Europe Leukotriene Receptor Antagonists for Asthma and COPD Sales by Country (2021-2026) & (K Units)
Table 45. Europe Leukotriene Receptor Antagonists for Asthma and COPD Revenue by Country (2021-2026) & ($ millions)
Table 46. Europe Leukotriene Receptor Antagonists for Asthma and COPD Sales by Type (2021-2026) & (K Units)
Table 47. Europe Leukotriene Receptor Antagonists for Asthma and COPD Sales by Application (2021-2026) & (K Units)
Table 48. Middle East & Africa Leukotriene Receptor Antagonists for Asthma and COPD Sales by Country (2021-2026) & (K Units)
Table 49. Middle East & Africa Leukotriene Receptor Antagonists for Asthma and COPD Revenue Market Share by Country (2021-2026)
Table 50. Middle East & Africa Leukotriene Receptor Antagonists for Asthma and COPD Sales by Type (2021-2026) & (K Units)
Table 51. Middle East & Africa Leukotriene Receptor Antagonists for Asthma and COPD Sales by Application (2021-2026) & (K Units)
Table 52. Key Market Drivers & Growth Opportunities of Leukotriene Receptor Antagonists for Asthma and COPD
Table 53. Key Market Challenges & Risks of Leukotriene Receptor Antagonists for Asthma and COPD
Table 54. Key Industry Trends of Leukotriene Receptor Antagonists for Asthma and COPD
Table 55. Leukotriene Receptor Antagonists for Asthma and COPD Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. Leukotriene Receptor Antagonists for Asthma and COPD Distributors List
Table 58. Leukotriene Receptor Antagonists for Asthma and COPD Customer List
Table 59. Global Leukotriene Receptor Antagonists for Asthma and COPD Sales Forecast by Region (2027-2032) & (K Units)
Table 60. Global Leukotriene Receptor Antagonists for Asthma and COPD Revenue Forecast by Region (2027-2032) & ($ millions)
Table 61. Americas Leukotriene Receptor Antagonists for Asthma and COPD Sales Forecast by Country (2027-2032) & (K Units)

+357 96 030922
info@marketpublishers.com

Table 62. Americas Leukotriene Receptor Antagonists for Asthma and COPD Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 63. APAC Leukotriene Receptor Antagonists for Asthma and COPD Sales Forecast by Region (2027-2032) & (K Units)
Table 64. APAC Leukotriene Receptor Antagonists for Asthma and COPD Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 65. Europe Leukotriene Receptor Antagonists for Asthma and COPD Sales Forecast by Country (2027-2032) & (K Units)
Table 66. Europe Leukotriene Receptor Antagonists for Asthma and COPD Revenue Forecast by Country (2027-2032) & ($ millions)
Table 67. Middle East & Africa Leukotriene Receptor Antagonists for Asthma and COPD Sales Forecast by Country (2027-2032) & (K Units)
Table 68. Middle East & Africa Leukotriene Receptor Antagonists for Asthma and COPD Revenue Forecast by Country (2027-2032) & ($ millions)
Table 69. Global Leukotriene Receptor Antagonists for Asthma and COPD Sales Forecast by Type (2027-2032) & (K Units)
Table 70. Global Leukotriene Receptor Antagonists for Asthma and COPD Revenue Forecast by Type (2027-2032) & ($ millions)
Table 71. Global Leukotriene Receptor Antagonists for Asthma and COPD Sales Forecast by Application (2027-2032) & (K Units)
Table 72. Global Leukotriene Receptor Antagonists for Asthma and COPD Revenue Forecast by Application (2027-2032) & ($ millions)
Table 73. Hetero Drugs Basic Information, Leukotriene Receptor Antagonists for Asthma and COPD Manufacturing Base, Sales Area and Its Competitors
Table 74. Hetero Drugs Leukotriene Receptor Antagonists for Asthma and COPD Product Portfolios and Specifications
Table 75. Hetero Drugs Leukotriene Receptor Antagonists for Asthma and COPD Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 76. Hetero Drugs Main Business
Table 77. Hetero Drugs Latest Developments
Table 78. Aurobindo Pharma Basic Information, Leukotriene Receptor Antagonists for Asthma and COPD Manufacturing Base, Sales Area and Its Competitors
Table 79. Aurobindo Pharma Leukotriene Receptor Antagonists for Asthma and COPD Product Portfolios and Specifications
Table 80. Aurobindo Pharma Leukotriene Receptor Antagonists for Asthma and COPD Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 81. Aurobindo Pharma Main Business
Table 82. Aurobindo Pharma Latest Developments
Table 83. Organon Pharma Basic Information, Leukotriene Receptor Antagonists for

+357 96 030922
info@marketpublishers.com

Asthma and COPD Manufacturing Base, Sales Area and Its Competitors
Table 84. Organon Pharma Leukotriene Receptor Antagonists for Asthma and COPD Product Portfolios and Specifications
Table 85. Organon Pharma Leukotriene Receptor Antagonists for Asthma and COPD Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 86. Organon Pharma Main Business
Table 87. Organon Pharma Latest Developments
Table 88. Kyorin Holdings Basic Information, Leukotriene Receptor Antagonists for Asthma and COPD Manufacturing Base, Sales Area and Its Competitors
Table 89. Kyorin Holdings Leukotriene Receptor Antagonists for Asthma and COPD Product Portfolios and Specifications
Table 90. Kyorin Holdings Leukotriene Receptor Antagonists for Asthma and COPD Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 91. Kyorin Holdings Main Business
Table 92. Kyorin Holdings Latest Developments
Table 93. Unichem Laboratories Basic Information, Leukotriene Receptor Antagonists for Asthma and COPD Manufacturing Base, Sales Area and Its Competitors
Table 94. Unichem Laboratories Leukotriene Receptor Antagonists for Asthma and COPD Product Portfolios and Specifications
Table 95. Unichem Laboratories Leukotriene Receptor Antagonists for Asthma and COPD Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 96. Unichem Laboratories Main Business
Table 97. Unichem Laboratories Latest Developments
Table 98. Dr Reddy's Laboratories Basic Information, Leukotriene Receptor Antagonists for Asthma and COPD Manufacturing Base, Sales Area and Its Competitors
Table 99. Dr Reddy's Laboratories Leukotriene Receptor Antagonists for Asthma and COPD Product Portfolios and Specifications
Table 100. Dr Reddy's Laboratories Leukotriene Receptor Antagonists for Asthma and COPD Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 101. Dr Reddy's Laboratories Main Business
Table 102. Dr Reddy's Laboratories Latest Developments
Table 103. Rising Pharma Basic Information, Leukotriene Receptor Antagonists for Asthma and COPD Manufacturing Base, Sales Area and Its Competitors
Table 104. Rising Pharma Leukotriene Receptor Antagonists for Asthma and COPD Product Portfolios and Specifications
Table 105. Rising Pharma Leukotriene Receptor Antagonists for Asthma and COPD Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)

+357 96 030922
info@marketpublishers.com

Table 106. Rising Pharma Main Business
Table 107. Rising Pharma Latest Developments
Table 108. Chiesi Farmaceutici Basic Information, Leukotriene Receptor Antagonists for Asthma and COPD Manufacturing Base, Sales Area and Its Competitors
Table 109. Chiesi Farmaceutici Leukotriene Receptor Antagonists for Asthma and COPD Product Portfolios and Specifications
Table 110. Chiesi Farmaceutici Leukotriene Receptor Antagonists for Asthma and COPD Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 111. Chiesi Farmaceutici Main Business
Table 112. Chiesi Farmaceutici Latest Developments
Table 113. Strides Pharma Basic Information, Leukotriene Receptor Antagonists for Asthma and COPD Manufacturing Base, Sales Area and Its Competitors
Table 114. Strides Pharma Leukotriene Receptor Antagonists for Asthma and COPD Product Portfolios and Specifications
Table 115. Strides Pharma Leukotriene Receptor Antagonists for Asthma and COPD Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 116. Strides Pharma Main Business
Table 117. Strides Pharma Latest Developments
Table 118. Shanghai Anbison Basic Information, Leukotriene Receptor Antagonists for Asthma and COPD Manufacturing Base, Sales Area and Its Competitors
Table 119. Shanghai Anbison Leukotriene Receptor Antagonists for Asthma and COPD Product Portfolios and Specifications
Table 120. Shanghai Anbison Leukotriene Receptor Antagonists for Asthma and COPD Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 121. Shanghai Anbison Main Business
Table 122. Shanghai Anbison Latest Developments
Table 123. CSPC Ouyi Pharmaceutical Basic Information, Leukotriene Receptor Antagonists for Asthma and COPD Manufacturing Base, Sales Area and Its Competitors
Table 124. CSPC Ouyi Pharmaceutical Leukotriene Receptor Antagonists for Asthma and COPD Product Portfolios and Specifications
Table 125. CSPC Ouyi Pharmaceutical Leukotriene Receptor Antagonists for Asthma and COPD Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 126. CSPC Ouyi Pharmaceutical Main Business
Table 127. CSPC Ouyi Pharmaceutical Latest Developments

+357 96 030922
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

Figure 1. Picture of Leukotriene Receptor Antagonists for Asthma and COPD
Figure 2. Leukotriene Receptor Antagonists for Asthma and COPD Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Leukotriene Receptor Antagonists for Asthma and COPD Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Leukotriene Receptor Antagonists for Asthma and COPD Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Leukotriene Receptor Antagonists for Asthma and COPD Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Leukotriene Receptor Antagonists for Asthma and COPD Sales Market Share by Country/Region (2025)
Figure 10. Leukotriene Receptor Antagonists for Asthma and COPD Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Montelukast
Figure 12. Product Picture of Zileuton
Figure 13. Product Picture of Others
Figure 14. Global Leukotriene Receptor Antagonists for Asthma and COPD Sales Market Share by Type in 2026
Figure 15. Global Leukotriene Receptor Antagonists for Asthma and COPD Revenue Market Share by Type (2021-2026)
Figure 16. Leukotriene Receptor Antagonists for Asthma and COPD Consumed in Hospital
Figure 17. Global Leukotriene Receptor Antagonists for Asthma and COPD Market: Hospital (2021-2026) & (K Units)
Figure 18. Leukotriene Receptor Antagonists for Asthma and COPD Consumed in Clinic
Figure 19. Global Leukotriene Receptor Antagonists for Asthma and COPD Market: Clinic (2021-2026) & (K Units)
Figure 20. Leukotriene Receptor Antagonists for Asthma and COPD Consumed in Others
Figure 21. Global Leukotriene Receptor Antagonists for Asthma and COPD Market: Others (2021-2026) & (K Units)
Figure 22. Global Leukotriene Receptor Antagonists for Asthma and COPD Sale Market

+357 96 030922
info@marketpublishers.com

Share by Application (2025)
Figure 23. Global Leukotriene Receptor Antagonists for Asthma and COPD Revenue Market Share by Application in 2026
Figure 24. Leukotriene Receptor Antagonists for Asthma and COPD Sales by Company in 2026 (K Units)
Figure 25. Global Leukotriene Receptor Antagonists for Asthma and COPD Sales Market Share by Company in 2026
Figure 26. Leukotriene Receptor Antagonists for Asthma and COPD Revenue by Company in 2026 ($ millions)
Figure 27. Global Leukotriene Receptor Antagonists for Asthma and COPD Revenue Market Share by Company in 2026
Figure 28. Global Leukotriene Receptor Antagonists for Asthma and COPD Sales Market Share by Geographic Region (2021-2026)
Figure 29. Global Leukotriene Receptor Antagonists for Asthma and COPD Revenue Market Share by Geographic Region in 2026
Figure 30. Americas Leukotriene Receptor Antagonists for Asthma and COPD Sales 2021-2026 (K Units)
Figure 31. Americas Leukotriene Receptor Antagonists for Asthma and COPD Revenue 2021-2026 ($ millions)
Figure 32. APAC Leukotriene Receptor Antagonists for Asthma and COPD Sales 2021-2026 (K Units)
Figure 33. APAC Leukotriene Receptor Antagonists for Asthma and COPD Revenue 2021-2026 ($ millions)
Figure 34. Europe Leukotriene Receptor Antagonists for Asthma and COPD Sales 2021-2026 (K Units)
Figure 35. Europe Leukotriene Receptor Antagonists for Asthma and COPD Revenue 2021-2026 ($ millions)
Figure 36. Middle East & Africa Leukotriene Receptor Antagonists for Asthma and COPD Sales 2021-2026 (K Units)
Figure 37. Middle East & Africa Leukotriene Receptor Antagonists for Asthma and COPD Revenue 2021-2026 ($ millions)
Figure 38. Americas Leukotriene Receptor Antagonists for Asthma and COPD Sales Market Share by Country in 2026
Figure 39. Americas Leukotriene Receptor Antagonists for Asthma and COPD Revenue Market Share by Country (2021-2026)
Figure 40. Americas Leukotriene Receptor Antagonists for Asthma and COPD Sales Market Share by Type (2021-2026)
Figure 41. Americas Leukotriene Receptor Antagonists for Asthma and COPD Sales Market Share by Application (2021-2026)

+357 96 030922
info@marketpublishers.com

Figure 42. United States Leukotriene Receptor Antagonists for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 43. Canada Leukotriene Receptor Antagonists for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 44. Mexico Leukotriene Receptor Antagonists for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 45. Brazil Leukotriene Receptor Antagonists for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 46. APAC Leukotriene Receptor Antagonists for Asthma and COPD Sales Market Share by Region in 2026
Figure 47. APAC Leukotriene Receptor Antagonists for Asthma and COPD Revenue Market Share by Region (2021-2026)
Figure 48. APAC Leukotriene Receptor Antagonists for Asthma and COPD Sales Market Share by Type (2021-2026)
Figure 49. APAC Leukotriene Receptor Antagonists for Asthma and COPD Sales Market Share by Application (2021-2026)
Figure 50. China Leukotriene Receptor Antagonists for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 51. Japan Leukotriene Receptor Antagonists for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 52. South Korea Leukotriene Receptor Antagonists for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 53. Southeast Asia Leukotriene Receptor Antagonists for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 54. India Leukotriene Receptor Antagonists for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 55. Australia Leukotriene Receptor Antagonists for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 56. China Taiwan Leukotriene Receptor Antagonists for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 57. Europe Leukotriene Receptor Antagonists for Asthma and COPD Sales Market Share by Country in 2026
Figure 58. Europe Leukotriene Receptor Antagonists for Asthma and COPD Revenue Market Share by Country (2021-2026)
Figure 59. Europe Leukotriene Receptor Antagonists for Asthma and COPD Sales Market Share by Type (2021-2026)
Figure 60. Europe Leukotriene Receptor Antagonists for Asthma and COPD Sales Market Share by Application (2021-2026)
Figure 61. Germany Leukotriene Receptor Antagonists for Asthma and COPD Revenue

+357 96 030922
info@marketpublishers.com

Growth 2021-2026 ($ millions)
Figure 62. France Leukotriene Receptor Antagonists for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 63. UK Leukotriene Receptor Antagonists for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 64. Italy Leukotriene Receptor Antagonists for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 65. Russia Leukotriene Receptor Antagonists for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 66. Middle East & Africa Leukotriene Receptor Antagonists for Asthma and COPD Sales Market Share by Country (2021-2026)
Figure 67. Middle East & Africa Leukotriene Receptor Antagonists for Asthma and COPD Sales Market Share by Type (2021-2026)
Figure 68. Middle East & Africa Leukotriene Receptor Antagonists for Asthma and COPD Sales Market Share by Application (2021-2026)
Figure 69. Egypt Leukotriene Receptor Antagonists for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 70. South Africa Leukotriene Receptor Antagonists for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 71. Israel Leukotriene Receptor Antagonists for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 72. Turkey Leukotriene Receptor Antagonists for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 73. GCC Countries Leukotriene Receptor Antagonists for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 74. Manufacturing Cost Structure Analysis of Leukotriene Receptor Antagonists for Asthma and COPD in 2026
Figure 75. Manufacturing Process Analysis of Leukotriene Receptor Antagonists for Asthma and COPD
Figure 76. Industry Chain Structure of Leukotriene Receptor Antagonists for Asthma and COPD
Figure 77. Channels of Distribution
Figure 78. Global Leukotriene Receptor Antagonists for Asthma and COPD Sales Market Forecast by Region (2027-2032)
Figure 79. Global Leukotriene Receptor Antagonists for Asthma and COPD Revenue Market Share Forecast by Region (2027-2032)
Figure 80. Global Leukotriene Receptor Antagonists for Asthma and COPD Sales Market Share Forecast by Type (2027-2032)
Figure 81. Global Leukotriene Receptor Antagonists for Asthma and COPD Revenue

+357 96 030922
info@marketpublishers.com

Market Share Forecast by Type (2027-2032)
Figure 82. Global Leukotriene Receptor Antagonists for Asthma and COPD Sales Market Share Forecast by Application (2027-2032)
Figure 83. Global Leukotriene Receptor Antagonists for Asthma and COPD Revenue Market Share Forecast by Application (2027-2032)

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Global Leukotriene Receptor Antagonists for Asthma and COPD Market Growth 2026-2032

Product link: https://marketpublishers.com/r/G0629D32E24FEN.html

Price: US$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/G0629D32E24FEN.html